Myriad Genetics IP Department
Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
Board of Regents of The University of Texas System
C Y G A G C G C
C12Q Y10T G01N A61P G01N C12Q G01N C12Q
inventional additional inventional inventional inventional inventional inventional additional
Xiaoyan Dihua Francisco J. Yoichi Aysegul A.
Zhou Yu Esteva Nagata Sahin